The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0343 ET - WuXi XDC Cayman retains its bull at Citi Research on strong growth visibility following its 1H results. The healthcare services company's management maintained its 2026 guidance for 30%-35% revenue compound annual growth over 2025-2030, while noting its total backlog--including milestone fees--has risen 62% on year, the Citi analysts note. It now expects a revenue CAGR in 2026-2035 of 26%, up from 24%, citing a stronger growth outlook. The bank raises its target price to 93.00 Hong Kong dollars from HK$73.00 and maintains a buy rating. Shares decline 3.6% to HK$77.30. (megan.cheah@wsj.com)

0145 ET - EssilorLuxottica's mainstay Ray-Ban eyewear brand could face a long-lasting reputational hit from privacy concerns associated with its line of smartglasses, Bernstein says. Ray-Ban's smart models, produced with tech giant Meta, have suffered a public backlash from fears that wearers might use them to record interlocutors without knowledge or consent. "Women are the primary victims of smartglasses misuse [and] Meta's smartglasses have become the lightning rod in the debate around privacy, surveillance and new technologies," Bernstein's analysts write. Damper expectations for the category could in reality be positive for EssilorLuxottica, given its likely dilutive effect on margins at the Franco-Italian group, they say. Still, "we wonder how much reputational damage has been done to the Ray-Ban brand," Bernstein says. (joshua.kirby@wsj.com; @johualeokirby)

0131 ET - Foundation Healthcare Holdings' long growth trajectory is supported by rising healthcare utilization and other tailwinds, Jefferies analysts say in a research report. This tailwind together with ambulatory care adoption and industry consolidation are quickening demand for lower-cost, coordinated care, the analysts say. The company is one of Singapore's largest private specialist platforms, and has a business model that combines specialist practices, medical centers and technology platform 'AVA' that produces benefits such as procurement efficiencies. The company's ambulatory facilities positions it to gain from migration of care out of hospitals. Jefferies initiates coverage of the stock with a buy rating and a target price of 1.10 Singapore dollars. Shares are 4.9% higher at S$0.75.